Biocon Strengthens Oncology Portfolio with Pertuzumab Biosimilar for HER2-Positive Breast Cancer

Biocon Ltd
Image Courtesy: Biocon Ltd

Biocon Limited has strengthened its oncology portfolio with its pertuzumab biosimilar, intended for use in treating patients with HER2-positive breast cancer across different stages of the disease. The biosimilar is indicated in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence. It is also indicated for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.

In the metastatic setting, pertuzumab is indicated in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic or locally recurrent, unresectable breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Biocon said extensive structural and functional analytical testing, along with comparative clinical pharmacokinetic data, demonstrated high similarity between its pertuzumab biosimilar and the reference product. The studies found no clinically meaningful differences in quality, safety or efficacy.

The addition of pertuzumab strengthens Biocon’s oncology portfolio, which includes treatments for solid tumours, including breast cancer, as well as supportive care therapies for chemotherapy-induced neutropenia. The company’s portfolio also covers bone health, including osteoporosis, treatment-related bone loss and skeletal complications associated with advanced cancers.

Breast cancer remains the most commonly diagnosed cancer among women in Europe. Estimates from the European Cancer Information System (ECIS) for 2024 identify it as the leading cancer diagnosis among women across the region. Around 15–20% of invasive breast cancers are associated with HER2 overexpression or amplification. Despite advances in HER2-targeted therapies, breast cancer continues to present a significant healthcare burden, making access to quality treatment an important priority for healthcare systems across Europe.

Biocon Limited (BSE: 532523; NSE: BIOCON) is a Bengaluru-headquartered global biopharmaceutical company focused on developing and supplying affordable medicines. Its portfolio includes biosimilars and generics across diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology and bone health.

The company has commercialised 12 biosimilar products and more than 30 generic formulations globally. Its research pipeline includes over 20 biosimilar assets, GLP-1 peptides and complex generics. Biocon operates in more than 120 countries, with seven manufacturing sites, three R&D facilities, 18 offices and over 9,500 employees. It was included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.